标题
EGFR/HER-targeted therapeutics in ovarian cancer
作者
关键词
-
出版物
Future Medicinal Chemistry
Volume 4, Issue 4, Pages 447-469
出版商
Future Science, LTD
发表日期
2012-03-15
DOI
10.4155/fmc.12.11
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Searching for a system: The quest for ovarian cancer biomarkers
- (2017) Karin D. Rodland et al. Cancer Biomarkers
- Phase I/II lapatinib plus carboplatin and paclitaxel in stage III or IV relapsed ovarian cancer patients
- (2017) S. E. Rivkin et al. JOURNAL OF CLINICAL ONCOLOGY
- The Role of Cytoreductive/Debulking Surgery in Ovarian Cancer
- (2017) Mark T. Wakabayashi et al. Journal of the National Comprehensive Cancer Network
- Cancer statistics, 2012
- (2012) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011
- (2011) A. Goldhirsch et al. ANNALS OF ONCOLOGY
- Identification of Immunoreactive Regions of Homology between Soluble Epidermal Growth Factor Receptor and α5-Integrin
- (2011) Jason A. Wilken et al. BIOCHEMISTRY
- p95HER2 and Breast Cancer
- (2011) J. Arribas et al. CANCER RESEARCH
- Phase II trial of lapatinib and topotecan (LapTop) in patients with platinum-refractory/resistant ovarian and primary peritoneal carcinoma
- (2011) S. John Weroha et al. GYNECOLOGIC ONCOLOGY
- A phase II evaluation of lapatinib in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: A gynecologic oncology group study
- (2011) Agustin A. Garcia et al. GYNECOLOGIC ONCOLOGY
- Big Costs for Little Gain in Ovarian Cancer
- (2011) Martee L. Hensley JOURNAL OF CLINICAL ONCOLOGY
- MEK1/2 Inhibitor Selumetinib (AZD6244) Inhibits Growth of Ovarian Clear Cell Carcinoma in a PEA-15-Dependent Manner in a Mouse Xenograft Model
- (2011) C. Bartholomeusz et al. MOLECULAR CANCER THERAPEUTICS
- Modeling high-grade serous ovarian carcinogenesis from the fallopian tube
- (2011) A. M. Karst et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The PI3 kinase/mTOR blocker NVP-BEZ235 overrides resistance against irreversible ErbB inhibitors in breast cancer cells
- (2010) Caroline Brünner-Kubath et al. BREAST CANCER RESEARCH AND TREATMENT
- The epidermal growth factor receptor conundrum
- (2010) Jason A. Wilken et al. CANCER
- HER Kinase Axis Receptor Dimer Partner Switching Occurs in Response to EGFR Tyrosine Kinase Inhibition despite Failure to Block Cellular Proliferation
- (2010) A. Jain et al. CANCER RESEARCH
- Vandetanib, Designed to Inhibit VEGFR2 and EGFR Signaling, Had No Clinical Activity as Monotherapy for Recurrent Ovarian Cancer and No Detectable Modulation of VEGFR2
- (2010) C. M. Annunziata et al. CLINICAL CANCER RESEARCH
- Phase II study of gefitinib in combination with paclitaxel (P) and carboplatin (C) as second-line therapy for ovarian, tubal or peritoneal adenocarcinoma (1839IL/0074)
- (2010) Patricia Pautier et al. GYNECOLOGIC ONCOLOGY
- A phase II study of erlotinib (OSI-774) given in combination with carboplatin in patients with recurrent epithelial ovarian cancer (NCIC CTG IND.149)
- (2010) H. Hirte et al. GYNECOLOGIC ONCOLOGY
- Erlotinib added to carboplatin and paclitaxel as first-line treatment of ovarian cancer: A phase II study based on surgical reassessment
- (2010) Stephanie V. Blank et al. GYNECOLOGIC ONCOLOGY
- Phosphatidic Acid Induces Ligand-independent Epidermal Growth Factor Receptor Endocytic Traffic through PDE4 Activation
- (2010) Andrés Norambuena et al. MOLECULAR BIOLOGY OF THE CELL
- Bevacizumab plus Low-Dose Metronomic Oral Cyclophosphamide in Heavily Pretreated Patients with Recurrent Ovarian Cancer
- (2010) Alfonso Sánchez-Muñoz et al. ONCOLOGY
- Trastuzumab Sensitizes Ovarian Cancer Cells to EGFR-targeted Therapeutics
- (2010) Jason A Wilken et al. Journal of Ovarian Research
- Trichostatin A sensitizes human ovarian cancer cells to TRAIL-induced apoptosis by down-regulation of c-FLIPL via inhibition of EGFR pathway
- (2009) Soo-Jung Park et al. BIOCHEMICAL PHARMACOLOGY
- HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy
- (2009) Jessica N McAlpine et al. BMC CANCER
- Trastuzumab-Induced HER Reprogramming in "Resistant" Breast Carcinoma Cells
- (2009) M. Narayan et al. CANCER RESEARCH
- Crosstalk Between Epidermal Growth Factor Receptor- and Insulin-Like Growth Factor-1 Receptor Signaling: Implications for Cancer Therapy
- (2009) J. Veeken et al. CURRENT CANCER DRUG TARGETS
- Update on Hsp90 Inhibitors in Clinical Trial
- (2009) Y. Kim et al. CURRENT TOPICS IN MEDICINAL CHEMISTRY
- Phase II trial of single agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rash
- (2009) Russell J. Schilder et al. GYNECOLOGIC ONCOLOGY
- Clinical Activity of Gemcitabine Plus Pertuzumab in Platinum-Resistant Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
- (2009) Sharmila Makhija et al. JOURNAL OF CLINICAL ONCOLOGY
- Biomarkers Predicting Clinical Outcome of Epidermal Growth Factor Receptor–Targeted Therapy in Metastatic Colorectal Cancer
- (2009) Salvatore Siena et al. JNCI-Journal of the National Cancer Institute
- A Naturally Occurring HER2 Carboxy-Terminal Fragment Promotes Mammary Tumor Growth and Metastasis
- (2009) K. Pedersen et al. MOLECULAR AND CELLULAR BIOLOGY
- Ovarian cancer: front-line standard treatment in 2008
- (2008) P. A. Vasey ANNALS OF ONCOLOGY
- Epidermal growth factor receptor gene copy number, K-ras mutation and pathological response to preoperative cetuximab, 5-FU and radiation therapy in locally advanced rectal cancer
- (2008) C. Bengala et al. ANNALS OF ONCOLOGY
- The ErbB signalling pathway: protein expression and prognostic value in epithelial ovarian cancer
- (2008) P de Graeff et al. BRITISH JOURNAL OF CANCER
- A phase Ib trial of docetaxel, carboplatin and erlotinib in ovarian, fallopian tube and primary peritoneal cancers
- (2008) P A Vasey et al. BRITISH JOURNAL OF CANCER
- Matuzumab Binding to EGFR Prevents the Conformational Rearrangement Required for Dimerization
- (2008) Judith Schmiedel et al. CANCER CELL
- Curcumin attenuates EGF-induced AQP3 up-regulation and cell migration in human ovarian cancer cells
- (2008) Chao Ji et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Priming with EGFR tyrosine kinase inhibitor and EGF sensitizes ovarian cancer cells to respond to chemotherapeutical drugs
- (2008) Cong Cao et al. CANCER LETTERS
- Mutant Epidermal Growth Factor Receptor in Benign, Borderline, and Malignant Ovarian Tumors
- (2008) K. D. Steffensen et al. CLINICAL CANCER RESEARCH
- The biological properties of cetuximab
- (2008) Bruno Vincenzi et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Implications of EGFR inhibition in ovarian cancer cell proliferation
- (2008) Shawna L. Bull Phelps et al. GYNECOLOGIC ONCOLOGY
- Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: A trial of the Chicago, PMH, and California Phase II consortia
- (2008) Halla S. Nimeiri et al. GYNECOLOGIC ONCOLOGY
- A phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced-stage ovarian, primary peritoneal, or fallopian tube cancer
- (2008) Jason Konner et al. GYNECOLOGIC ONCOLOGY
- Phase II trial of cetuximab and carboplatin in relapsed platinum-sensitive ovarian cancer and evaluation of epidermal growth factor receptor expression: A Gynecologic Oncology Group study
- (2008) Angeles Alvarez Secord et al. GYNECOLOGIC ONCOLOGY
- A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations
- (2008) Ann K. Folkins et al. GYNECOLOGIC ONCOLOGY
- Chemoresistant tumor cell lines display altered epidermal growth factor receptor and HER3 signaling and enhanced sensitivity to gefitinib
- (2008) Tiziana Servidei et al. INTERNATIONAL JOURNAL OF CANCER
- Rab-coupling protein coordinates recycling of α5β1 integrin and EGFR1 to promote cell migration in 3D microenvironments
- (2008) Patrick T. Caswell et al. JOURNAL OF CELL BIOLOGY
- Reversal of Drug Resistance in Ovarian Cancer: Where Do We Go From Here?
- (2008) Stan B. Kaye JOURNAL OF CLINICAL ONCOLOGY
- HER receptor signaling confers resistance to the insulin-like growth factor-I receptor inhibitor, BMS-536924
- (2008) P. Haluska et al. MOLECULAR CANCER THERAPEUTICS
- HER2Status and Benefit from Adjuvant Trastuzumab in Breast Cancer
- (2008) Soonmyung Paik et al. NEW ENGLAND JOURNAL OF MEDICINE
- K-rasMutations and Benefit from Cetuximab in Advanced Colorectal Cancer
- (2008) Christos S. Karapetis et al. NEW ENGLAND JOURNAL OF MEDICINE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started